Form 4: Director Sells UTHR Stock Under 10b5-1 Plan

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $495.01 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Jan Malcolm, a Director of United Therapeutics Corporation (UTHR), reported a sale of common stock.
• The transaction involved the disposition of 50 shares of common stock.
• The shares were sold at a price of $495.01 per share.
• The sale occurred on January 5, 2026.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was established by the reporting person on September 11, 2025.
• Following this transaction, Jan Malcolm directly beneficially owns 370 shares of common stock.

Sentiment

Score: 5

Explanation: The sale of 50 shares by a director under a pre-arranged 10b5-1 plan is a routine insider transaction and does not indicate a significant change in company outlook or fundamental performance. The small volume of shares sold further contributes to a neutral sentiment.

Positives

• NA

Negatives

• A director's sale of company stock, even if pre-planned, reduces insider ownership, which can sometimes be perceived as a slight negative signal by investors.

Risks

• The sale of shares by an insider, regardless of the reason, can sometimes be misinterpreted by the market, potentially leading to unwarranted speculation about the company's future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is specific to an individual director's personal trading activity and does not directly reflect broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Minimal impact due to the small number of shares sold and the pre-planned nature of the transaction, which typically reduces concerns about opportunistic selling.

Key Dates

Recommendation

The sale of 50 shares by a director, executed under a pre-established 10b5-1 trading plan, is a routine event and does not provide sufficient new information to alter an existing investment thesis for United Therapeutics Corporation. The transaction volume is too small to indicate a significant change in insider sentiment or company fundamentals, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, Beneficial Ownership